J. Sorich

发表

Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival.

H. Yee, A. Zeleniuch‐Jacquotte, E. Newcomb, 2001, Human pathology.

Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors.

A. Zeleniuch‐Jacquotte, E. Newcomb, R. Demopoulos, 1999, The American journal of pathology.

Oxaliplatin: practical guidelines for administration.

H. Hochster, A. Wagner, J. Sorich, 2004, Clinical journal of oncology nursing.

Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.

E. Plimack, C. Runowicz, S. Wadler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intraperitoneal Topoisomerase‐I Inhibitors: Preliminary Findings with 9‐Aminocamptothecin

H. Hochster, F. Muggia, A. Hamilton, 2000, Annals of the New York Academy of Sciences.

Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group.

C. Runowicz, S. Wadler, H. Hochster, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer.

A. Zeleniuch‐Jacquotte, H. Hochster, U. Beller, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.

H. Hochster, A. Chachoua, L. Liebes, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study.

H. Hochster, F. Muggia, P. Ivy, 2008, Gynecologic oncology.

Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity.

A. Zeleniuch‐Jacquotte, H. Hochster, A. Chachoua, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies

A. Pavlick, Mimi Kim, H. Hochster, 2003, Anti-cancer drugs.

Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels.

J. Doroshow, L. Leong, S. Akman, 1995, Gynecologic oncology.

Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy.

N. Colombo, H. Hochster, F. Muggia, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy.

Mimi Kim, F. Muggia, J. Curtin, 2003, Hematology/oncology clinics of North America.

Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days

S. Wadler, H. Hochster, F. Muggia, 2002, Anti-cancer drugs.

A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting

S. Taneja, F. Muggia, A. Hamilton, 2003, Anti-cancer drugs.

Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen

J. Sorich, S. Sewak, J. O'LEARY, 2006, Anti-cancer drugs.

Phase I Study of Combined Pegylated Liposomal Doxorubicin with Protracted Daily Topotecan for Ovarian Cancer

Sang Lee, Anne Hamilton, H. Yee, 2005, Clinical Cancer Research.

Gemcitabine plus cisplatin combination given with amifostine (GAP) to heavily pretreated patients with gynecologic and peritoneal cancers: tolerance and activity in ovarian cancer.

F. Muggia, T. Safra, J. Sorich, 1998, Anti-cancer drugs.

Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.

A. Zeleniuch‐Jacquotte, H. Hochster, A. Chachoua, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase IB study of low-dose intraperitoneal recombinant interleukin-2 in patients with refractory advanced ovarian cancer: rationale and preliminary report.

U. Beller, M. Dugan, A. Chachoua, 1989 .

Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer

H. Yee, H. Hochster, F. Muggia, 2002, Journal of Gastrointestinal Surgery.

Intraperitoneal carboplatin: rationale and experience.

J. Speyer, J. Sorich, 1992, Seminars in oncology.

A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor

A. Pavlick, H. Hochster, F. Muggia, 2004, Anti-cancer drugs.

Expression of the Cell Cycle Inhibitor p27 KIP1 Is a New Prognostic Marker Associated with Survival in Epithelial Ovarian Tumors

A. Zeleniuch‐Jacquotte, E. Newcomb, R. Demopoulos, 1998 .

Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2′-deoxyuridine

C. Russell, N. Colombo, F. Muggia, 2004, Cancer Chemotherapy and Pharmacology.

A Phase I Trial of Cyclosphosphamide and Carboplatinum Combined with Interleukin-3 in Women with Advanced-Stage Ovarian Cancer

C. Cohen, C. Runowicz, S. Wadler, 1995 .

Phase IB study of low‐dose intraperitoneal recombinant interleukin‐2 in patients with refractory advanced ovarian cancer: Rationale and preliminary report

U. Beller, M. Dugan, A. Chachoua, 1990, Gynecologic oncology.

Phase I study of paclitaxel (P) combined with 14-day topotecan (T) Continuous IV (CIV) infusion in previously treated and untreated patients (PTS)

H. Hochster, A. Chachoua, J. Speyer, 1997 .